The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in the spotlight after the FDA accepted its New Drug Application for TLX101-Px (Pixclara®), a PET imaging agent for glioma. TLX101-Px has received Orphan Drug and Fast Track status, with a key regulatory decision expected by September.
Image source: Getty Images
What did Telix Pharmaceuticals report?
- The US FDA accepted Telix's NDA for TLX101-Px (Pixclara®), a PET agent for imaging brain cancer (glioma)
- The Prescription Drug User Fee Act (PDUFA) goal date is 11 September 2026
- TLX101-Px holds Orphan Drug and Fast Track designations in the US
- No FY 2026 revenue guidance has been assigned to TLX101-Px pending approval
- TLX101-Px aimed at addressing an unmet medical need in both adult and paediatric glioma cases
What else do investors need to know?
The FDA's acceptance of the Telix NDA marks a key step toward potential commercialisation of TLX101-Px in the United States. This diagnostic agent aims to improve the differentiation between recurrent glioma and treatment-related changes, a persistent challenge in neuro-oncology.
TLX101-Px is expected to complement Telix's broader LAT1-targeting therapeutic pipeline, notably the TLX101-Tx therapy under investigation in the IPAX-BrIGHT clinical trial. There are currently no marketing authorisations for TLX101-Px or TLX101-Tx in any region.
Telix has reaffirmed that FY 2026 guidance does not anticipate revenue for TLX101-Px, pending the FDA decision. The product could provide both clinical impact and financial upside if approved in the future.
What's next for Telix Pharmaceuticals?
Investors can expect further updates as Telix works with the FDA ahead of the September 2026 goal date for TLX101-Px. The company is also advancing late-stage trials for related therapies, aiming to build a broader radiopharmaceutical portfolio for oncology and rare diseases.
Looking ahead, a successful approval could see Telix expand its presence in the US diagnostics market while pursuing commercial opportunities for both imaging and therapeutic candidates.
Telix Pharmaceuticals share price snapshot
Over the past year, Telix Pharmaceuticals shares have declined 49%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 16% over the same period.
